Could COVID-19 be a catalyst for virtualizing clinical trials?

The virtualization of clinical trials has long been technically feasible, but cultural and regulatory barriers have prevented implementation. With over 1200 clinical trials worldwide being...
Learn More

COVID-19: a catalyst for anti-infective investing?

There has been a persistent call from early stage innovators to shine a spotlight on building anti-infective defenses in light of the looming crisis of antimicrobial resistance (AMR). Unfortunately,...
Learn More

The risk-reward balance in drug repurposing

Does drug repurposing overcome the hurdles and pitfalls in drug development? Having conducted several recent due diligence exercises in the repurposing space, we discuss the gems and the hidden...
Learn More

Monetizing the microbiome

Based on some neat guesstimating1, the number of bacteria in the gut roughly equals the number of cells in our bodies, so it’s no surprise that such a substantial (around 200g in a 70kg adult) and...
Learn More

Is Gilead’s Selonsertib for NASH Dead?

Title: Is Gilead’s Selonsertib for NASH Dead? Author: Peter G. Traber, MD Date: 02/12/2019 Introduction The search for an effective therapy for NASH with advanced fibrosis/cirrhosis suffered a major...
Learn More

Orkambi UK - Sound and Fury

By Anthony Walker, PhD, Managing Partner There’s a lot of sound and fury about Orkambi in the UK. Following a rejection from NICE, Vertex and NHS England have not been able to reach terms and the...
Learn More

Why Every Biotech Needs a Scouting Function

Title: Why Every Biotech Needs a Scouting Function Author: Chris Owens, PhD What is asset scouting? Simply put, it is a search to identify and evaluate pharmaceutical assets or partners for...
Learn More

microRNAs as drug targets

microRNAs as drug targets Saadia Basharat, PhD, Senior Consultant microRNAs (miRNA) are small noncoding RNAs that regulate the expression of multiple target genes by either blocking the translation...
Learn More

Infographic: Britain crashes out of favor with US pharmaceutical executives

Britain crashes out of favor with US pharmaceutical executives The biotech industry is a pillar of the knowledge economy, with governments around the world investing heavily to attract capital and...
Learn More

NASH Surprises and Interpretation of Clinical Trials

Title: NASH Surprises and Interpretation of Clinical Trials Author: Peter G. Traber, MD Introduction 2019 will usher in a new chapter in NASH drug development with data reported on the first phase 3...
Learn More

Pharma Defying Gravity – How Much Longer?

Anthony Walker, PhD, Managing Partner, Alacrita Consulting
Learn More

Agencies Clarify NASH Endpoints—But Don’t Harmonize

Title: Agencies Clarify NASH Endpoints—But Don’t Harmonize Author: Peter G. Traber, MD The FDA and EMA have recently published very similar clinical trial endpoints for pre-cirrhotic NASH, with one...
Learn More
1 2 3